글로벌 정신분열증 치료 시장 – 2028년까지의 산업 동향 및 예측

정신분열증 치료에 대한 시장 분석 및 통찰력

정신분열증 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 2028년까지 시장이 88억 6천만 달러에 이를 것으로 분석하고, 위에 언급된 예측 기간 동안 2.65%의 CAGR로 성장할 것이라고 예측했습니다.

정신분열증은 실체의 라이프스타일에 바람직하지 않은 영향을 미치는 만성 장애의 한 유형입니다. 정신분열증 환자는 비정상적으로 현실을 해석합니다. 이 장애는 망상과 환각을 그룹화하는 다양한 행동 변화를 초래합니다. 정신분열증 치료는 평생의 과정이며, 정신분열증 치료에 사용되는 약물은 환자의 활동을 제어합니다.

생활 방식의 변화로 인해 정신분열증 장애의 발병률이 빠르게 증가하는 것은 정신분열증 치료 시장의 성장과 수요를 강화하는 필수 요인 중 하나입니다. 게다가, 강력한 R&D 활동도 ​​2021년에서 2028년까지의 예측 기간 동안 글로벌 시장이 성장하는 데 기여하고 있습니다. 또한 마약,  알코올  및 기타와 같은 다양한 중독의 발병률이 빠르게 증가하고 치료를 찾는 환자 수가 증가하고 더 나은 의료 인프라에 대한 수요가 증가함에 따라 시장 성장이 강화되고 있습니다. 마찬가지로, 고령자 수가 증가하고 새로운 약물과 치료법도 도입되어 위에서 언급한 예측 기간 동안 시장 성장이 촉진되고 있습니다.  의료 의 급속한 발전  과 의사와 환자의 정교한 치료법에 대한 높은 수요는 정신분열증 치료 시장 확장을 더욱 가속화할 것이며 2021년에서 2028년까지의 예측 기간 동안 시장에 상당한 성장 기회를 제공하고 있습니다.

그러나 의료 인프라 부족과 함께 R&D 및 치료의 막대한 비용은 정신분열증 치료 시장의 성장을 제한할 것입니다. 반면, 세계 일부 지역에서 인식 부족은 정신분열증 치료 시장의 발전에 도전할 수 있습니다.

This schizophrenia treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on schizophrenia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Schizophrenia Treatment Market Scope and Market Size

Schizophrenia treatment market is segmented on the basis of therapeutic class, product type, treatment and end users. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• The therapeutic class segment of schizophrenia treatment market is segmented into third-generation antipsychotics, second-generation antipsychotics and others.
• On the basis of product type, the schizophrenia treatment market is segmented into medications, conventional or typical antipsychotic drugs, atypical antipsychotic drugs and therapies.
• Based on risk in treatment, the schizophrenia treatment market is segmented into oral and injectable.
• The end users segment of the schizophrenia treatment market is segmented into hospitals including hospital pharmacies, retail pharmacies and rehabilitation centers.

Schizophrenia Treatment Market Country Level Analysis

Schizophrenia treatment market is analyzed and market size insights and trends are provided by country, therapeutic class, product type, treatment and end users as referenced above.

The countries covered in the  schizophrenia treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

North America region leads the schizophrenia treatment market owing to the growing prevalence of schizophrenia, rising geriatric population and increasing demand for schizophrenia treatment within the region. Asia-Pacific is expected to expand at a significant growth rate over the forecast period of 2021 to 2028 because of the rapidly increasing population and growing demand for technologically advanced treatments in this particular region.

The country section of the schizophrenia treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Schizophrenia treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for schizophrenia treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the schizophrenia treatment market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Schizophrenia Treatment Market Share Analysis

Schizophrenia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to schizophrenia treatment market.

정신분열증 치료 시장 보고서에서 다루는 주요 기업으로는 Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Otsuka Holdings Co. Ltd., AstraZeneca, Eli Lilly and Company, Alkermes, Sumitomo Dainippon Pharma Co. Ltd., Pfizer Inc., VANDA PHARMACEUTICALS, Mayo Foundation for Medical Education and Research(MFMER), Allergan, H. Lundbeck A/S, AVINEURO PHARMACEUTICALS, Gedeon Richter plc, Astellas Pharma Inc., Novartis AG, AbbVie Inc., PsychoGenics Inc., Merz Pharma 등이 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다. 

SKU-27284